NCT02583243

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 209 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Project BEST is a clinical project funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) to increase treatment to opiate dependent patients with mental illness in New Haven, CT and to prospectively follow everyone enrolled in buprenorphine care for as long as the individual takes buprenorphine to track the success of buprenorphine for the maintenance of opiate dependence.

Detailed description

The investigators propose to create a prospective cohort that will track outcomes for an opiate dependent population on buprenorphine maintenance. Individuals who have already decided to undergo buprenorphine treatment in Project BEST will be invited to participate in the following data collection process. The investigators propose the following series of data collection to assess clients during their time in the cohort: GPRA, supplemental instrument, ASI, SCID, COWS, Urine toxicology. Patients who are enrolled will enter a standardized, manual based weekly counseling regimen. Urine toxicology will be performed a minimum of twice monthly, but will not occur at the same times monthly to decrease the probability of sampling error. This is a prospective cohort to follow a group of individuals on buprenorphine treatment. The goal of this prospective cohort is to generate thoughtful observations. Specific items of interest which will be compared with age, race matched historical controls on methadone will be: 1. Changes in addiction severity over treatment time 2. Changes in sexual risk behaviors and injection practices 3. Improvements in urine toxicology 4. Co-occurring mental illness

Conditions

• Opioid-related Disorders
• HIV Infections
• Hepatitis C, Chronic
• Depression

Interventions

Type	Name	Description
BEHAVIORAL	MET/CBT based individualized counseling	Manualized counseling with the first four week being MET followed by 8 weeks of CBT
DRUG	Buprenorphine	Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.

Timeline

• Start date: 2005-05-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2015-10-22
• Last updated: 2020-04-03

Locations

1 site across 1 country: United States